Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Similar documents
Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

SKIN CANCER. Most common cancer diagnosis 40% of all cancers

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

NAACCR Webinar Series 1

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

47. Melanoma of the Skin

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Clinical characteristics

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

NEW SURGICAL APPROACHES TO MELANOMA THERAPY

Melanoma Quality Reporting

Malignant Melanoma Early Stage. A guide for patients

Protocol applies to melanoma of cutaneous surfaces only.

Precision Surgery for Melanoma

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Radionuclide detection of sentinel lymph node

Melanoma: The Basics. What is a melanocyte?

Surgery for Melanoma and What s on the Horizon

1. Opdivo + Ipilumimab is now the first line therapy for metastatic melanoma.

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Professor Michael Eccles

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Melanoma Update: 8th Edition of AJCC Staging System

Epidemiology. Objectives 8/28/2017

When Do I Consider Myself Cured?

1

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Malignant Melanoma Introduction increasing incidence increasing mortality skin >50% normal skin pigmented lesion

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:

Racial differences in six major subtypes of melanoma: descriptive epidemiology

STAGE CATEGORY DEFINITIONS

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

Multiple Primary Melanoma in a Thai Male: A Case Report

NAACCR Hospital Registry Webinar Series

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma. Lynn Schuchter, M.D. Associate Professor of Medicine Abramson Cancer Center of the University of Pennsylvania

Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES

Living Beyond Cancer Skin Cancer Detection and Prevention

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

Epithelial Cancer- NMSC & Melanoma

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds

Melanoma of the Skin

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Kentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

Controversies and Questions in the Surgical Treatment of Melanoma

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna

Printed by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive

Characteristics and Treatment of Cutaneous Melanoma of the Foot

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Pathology of the skin. 2nd Department of Pathology, Semmelweis University

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Impact of Prognostic Factors

Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients

Michael T. Tetzlaff MD, PhD

Melanoma. Walt Mudie - Block 5

Melanoma Case Scenario 1

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

Melanoma Case Scenario 1

3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer

Corporate Medical Policy

Malignant tumors of melanocytes: Part 1. Deba P Sarma, MD., Omaha

Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Melanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms

Michael T. Tetzlaff MD, PhD

Technical Considerations. Imaging Considerations

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

WHAT DOES THE PATHOLOGY REPORT MEAN?

Practice of Axilla Surgery

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

ACRIN 6666 Therapeutic Surgery Form

Nodal Treatment in Melanoma: Snow to MSLT-II

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Prognostic Variables and Surgical Management of Foot Melanoma: Review of a 25-Year Institutional Experience

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Directly Coded Summary Stage Melanoma

Dr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland

Chapter 2 Staging of Breast Cancer

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

AJCC Cancer Staging 8 th Edition

Transcription:

Melanoma Kaushik Mukherjee MD A. Scott Pearson MD

Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston

Melanoma Basics 8 th most common cancer in US, 4 5% of all skin cancers 62,190 new cases per year, 7,910 deaths in 2006 20 times more frequent in Caucasians than African Americans or Asians Risk factors UV exposure Congenital nevi, Dysplastic nevus syndrome, Spitz nevi Xeroderma pigmentosum Non melanoma skin cancer Family history of melanoma (5 10%) Chr 1p sporadic and familial melanoma Chr 9p sporadic melanoma alone Somatic mutations in p16 tumor suppressor gene (not so sweet 16)

Common Clinical Features Asymmetric outline Borders changing/irregular Color variation (not always) Diameter > 6mm i o n Also: unknown primary melanoma and noncutaneous melanoma

Types of Melanoma 70% not always sun damaged skin flat, dark pigment, radial growth thickens as vertical growth develops 15% early vertical growth worst prognosis 5% subungual, palms and soles most common type in African Americans Delayd dx, poor prognosis Nodular Superficial Spreading 10% older individuals, sun damaged skin flat, dark pigment, irregular borders slow development good prognosis due to superficial nature Lentigo maligna Acral lentiginous

Hope that the Cancer is only Skin Deep

How to Interpret Melanoma Staging 1: 1mm 2: 1<x 2mm 3: 2<x 4mm 4: >4mm a = no ulceration b = ulceration 0: no nodes 1: 1 node 2: 2 3 nodes OR in transit with no nodes 3: 4+ nodes, Matted, In transit, or Satellites with nodes a = micro mets b = clinically apparent mets 0: none 1: metastasis a = skin, subq, or distant LN b = lung C = any other met or met + increased LDH

GROUPING PATHOLOGIC STAGE Tumor Node Metastasis 0 Tis N0 M0 IA T1a N0 M0 IB T1b N0 M0 T2a N0 M0 IIA T2b N0 M0 T3a N0 M0 IIB T3b N0 M0 T4a N0 M0 IIC T4b N0 M0 IIIA T1 4a N1a M0 T1 4a N2a M0 IIIB T1 4b N1a M0 T1 4b N2a M0 T1 4a N1b M0 T1 4a N2b M0 T1 4a/b N2c M0 IIIC T1 4b N1b M0 T1 4b N2b M0 Any T N3 M0 IV Any T Any N M1

Survival by Stage in Melanoma

IB Yes T1b 80 No T2a 80 IIA Yes T2b 65 No T3a 65 IIB Yes T3b 50 No T4a 55 IIC Yes T4b 35 IIIA No N1a 70 No N2a 60 IIIB Yes N1a 55 Yes N2a 50 No N1b 55 No N2b 45 IIIC Yes N1b 30 Yes N2b 25 Yes or No N3 30 Effect of Ulceration on Survival STAGE TUMOR ULCERATION T STAGE APPROXIMATE 10 YEAR SURVIVAL (%) IA No T1a 90

Survival by Thickness in Localized Melanoma

Survival by Number of Positive Nodes in Node Positive Melanoma

The next step should be 1. Amputation 2. Isolated limb perfusion 3. Sentinel LN Bx 44% 22% 28% 4. Local excision and skin grafting 5. Excision with regional LN dissection Amputation 0% Isolated limb... 6% Sentinel LN Bx Local excision... Excision with...

The SESAP Answer Foot melanoma has a worse prognosis than more proximal disease. Women and Celtic people are more likely to have this problem. Surgical resection is the mainstay of treatment Amputation is relevant for subungual melanoma and in transit mets developing after excision of the primary lesion Sentinel Lymph Node Biopsy is the first step in evaluating this patient If positive, no amputation as no chance for cure If positive, local control with excision and wound coverage Limb perfusion +/ hyperthermia is for Recurrence Bulky disease

Management Algorithm

Vitamin A The next step should be 1. Re excision with 2 cm margins 2. Levamisole/BCG 3. Lymphoscintigraphy 4. Interferon 5. Vitamin A 48% 0% 43% 5% 5% Re excision wi... Levamisole/BCG Lymphoscintigr... Interferon

The SESAP Answer This lesion is less than 1 mm thick but ULCERATED (Stage T1b) Ulceration increases risk of LN mets SLN Bx This lesion is on the trunk 30% risk of non anatomic lymphatic drainage, so LYMPHISCINTIGRAPHY is necessary Other options 1 cm margin is adequate for a T1 lesion Interferon therapy ONLY IF NODE POSITIVE Vitamin A could improve your eyesight to allow you to detect recurrence earlier but is otherwise useless

SLN Bx for melanoma 1. Predicts prognosis 2. Improves survival 3. Is for melanomas < 1mm thick 4. Has a 23% complication rate 5. Should be followed with LN dissection if positive 64% 36% 0% 0% 0% Predicts progn... Improves survi... Is for melanom... Has a 23% comp... Should be foll...

The SESAP Answer Tumor Thickness Probability of Positive Node SLN Bx is a powerful PROGNOSTIC tool. Complication rates: 4% SLN Bx < 0.8mm 1% 0.8mm x < 1.5mm 8% 1.5mm x < 4.0mm 23% 4.0mm 36% 23 % SLN Bx + completion LN dissection Perform in thin (< 1mm) melanomas if ulcerated or Clark level IV V invasion Need more study to determine benefit of completion LN dissection if a positive SLN Bx

Sentinel Lymph Node Bx By using isotope lymphatic mapping, an intraop gamma probe, and intraop injection of blue dye, the SLN can be identified in more than 95% of cases in the groin and axilla in 85% of cases in the head/neck region Resect all nodes that are BLUE HOT (>10% of max gamma count)

Sentinel Lymph Node Bx Indications All melanomas greater than 1mm thickness If clinically positive nodes without distant mets LYMPH NODE DISSECTION If POSITIVE SLN Bx LYMPH NODE DISSECTION although benefit not completely clear

Sentinel Lymph Node Bx How to Do It Intradermally inject Tc99 sulfur colloid into perimeter of biopsy scar approx 90 180 min preop Perform lymphiscintigraphy and label areas of uptake Intradermally inject isosulfan blue into perimeter of biopsy scar in OR Use gamma probe to localize hottest area Make 2 4 cm incision Dissect bluntly until you find a blue lymphatic and follow to a blue node Use gamma probe and identify/resect all blue or hot nodes

Sentinel Lymph Node Mapping

Margin for re excision? 1. None 2. 0.5cm 3. 1cm 4. 2cm 5. 5cm 68% 18% 9% 0% 5% None 0.5cm 1cm 2cm 5cm

The First Cut is the Deepest, but the Second Cut is Wider TUMOR THICKNESS (mm) MARGIN RADIUS (cm) In situ 0.5 <1.0 1.0 1 2 1.0 2.0 >2.0 2.0

Take Home Points Depth of invasion correlates with likelihood of metastasis, width of primary excision, and survival Sentinel LN Bx is highly effective for patients with >1mm thick melanomas and no clinically apparent metastases or thin melanomas with ulcers or Clark IV or V If you know melanoma, you can get a good score on the ABSITE